Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:8:109-19.
doi: 10.1007/8904_2012_168. Epub 2012 Jul 29.

A Systematic Review of BH4 (Sapropterin) for the Adjuvant Treatment of Phenylketonuria

Mary Lou Lindegren  1 , Shanthi Krishnaswami, Tyler Reimschisel, Christopher Fonnesbeck, Nila A Sathe, Melissa L McPheeters
Affiliations

A Systematic Review of BH4 (Sapropterin) for the Adjuvant Treatment of Phenylketonuria

Mary Lou Lindegren et al. JIMD Rep. 2013.

Abstract

Context: Dietary management is the mainstay of effective treatment in PKU, but dietary restriction is difficult and additional treatment options are needed.

Objective: To systematically review evidence regarding sapropterin (BH4) use as an adjunct to dietary restriction in individuals with PKU.

Data sources: Five databases including MEDLINE up to August 2011.

Study selection: Two reviewers independently assessed studies against predetermined inclusion/exclusion criteria.

Data extraction: Two reviewers independently extracted data regarding participant and intervention characteristics and outcomes and assigned overall quality and strength of evidence ratings based on predetermined criteria.

Results: BH4 research includes two randomized controlled trials (RCTs) and three uncontrolled open-label trials. Phenylalanine (Phe) levels were reduced by at least 30 % in up to half of treated participants (32-50 %). In one RCT comparing placebo on likelihood of a 30 % reduction in Phe, 9 % of those on placebo achieved this effect, compared with 44 % of the treated group after 6 weeks. Phe tolerance and variability were improved in treated participants in studies assessing those outcomes. No comparative studies assessed long-term outcomes including cognitive effects, nutritional status, or quality of life.

Conclusions: Adjuvant pharmacologic therapy has the potential to support individuals in achieving optimal Phe levels. BH4 has been shown to reduce Phe levels in some individuals, with significantly greater reductions seen in treated versus placebo groups. The strength of the evidence is moderate for short-term effects on reducing Phe in a subset of initially BH4-responsive individuals, moderate for a lack of significant harms, low for longer-term effects on cognition, and insufficient for all other outcomes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow of studies identified for the review. *The total number of articles in the exclusion categories exceeds the number of articles excluded because most of the articles fit into multiple exclusion categories. BH4 sapropterin, N number
See this image and copyright information in PMC

References

    1. Agency for Healthcare Research and Quality (2008) Methods guide for effectiveness and comparative effectiveness reviews. AHRQ publication No. 10(12)-EHC063-EF. Agency for Healthcare Research and Quality, Rockville, MD, April 2012. Chapters available at: www.effectivehealthcare.ahrq.gov - PubMed
    1. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417–1427. doi: 10.1016/S0140-6736(10)60961-0. - DOI - PubMed
    1. Burlina A, Blau N. Effect of BH(4) supplementation on phenylalanine tolerance. J Inherit Metab Dis. 2009;32:40–45. doi: 10.1007/s10545-008-0947-1. - DOI - PubMed
    1. Burton BK, Grange DK, Milanowski A, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis. 2007;30:700–707. doi: 10.1007/s10545-007-0605-z. - DOI - PubMed
    1. Burton BK, Bausell H, Katz R, Laduca H, Sullivan C. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU) Mol Genet Metab. 2010;101:110–114. doi: 10.1016/j.ymgme.2010.06.015. - DOI - PubMed

LinkOut - more resources